{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:24:55Z","timestamp":1793967895260,"version":"4.8.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":246,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023MH206"],"award-info":[{"award-number":["ZR2023MH206"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019446","name":"Medical and Health Science and Technology Development Project of Shandong Province","doi-asserted-by":"publisher","award":["202204071065"],"award-info":[{"award-number":["202204071065"]}],"id":[{"id":"10.13039\/501100019446","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81702935"],"award-info":[{"award-number":["81702935"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clinsp.2026.101147","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:18:49Z","timestamp":1788949129000},"page":"101147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5758-2132","authenticated-orcid":false,"given":"Le","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7575-1445","authenticated-orcid":false,"given":"Kang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0381-3853","authenticated-orcid":false,"given":"Lei","family":"Bo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5098-7163","authenticated-orcid":false,"given":"Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clinsp.2026.101147_bib0001","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2019-215707","article-title":"Do patients with axial spondyloarthritis with radiographic sacroiliitis fulfil both the modified New York criteria and the ASAS axial spondyloarthritis criteria? Results from eight cohorts","volume":"78","author":"Boel","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinsp.2026.101147_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1376525","article-title":"Gut microbiota dysbiosis in ankylosing spondylitis: a systematic review and meta-analysis","volume":"14","author":"Su","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"issue":"26","key":"10.1016\/j.clinsp.2026.101147_bib0003","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1056\/NEJMra1406182","article-title":"Ankylosing spondylitis and axial spondyloarthritis","volume":"374","author":"Taurog","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinsp.2026.101147_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41413-019-0057-8","article-title":"Ankylosing spondylitis: etiology, pathogenesis, and treatments","volume":"7","author":"Zhu","year":"2019","journal-title":"Bone Res"},{"issue":"2","key":"10.1016\/j.clinsp.2026.101147_bib0005","first-page":"263","article-title":"Incidence and prevalence of axial spondyloarthritis: methodologic challenges and gaps in the literature","volume":"36","author":"Bohn","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101147_bib0006","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"suppl_6","key":"10.1016\/j.clinsp.2026.101147_bib0007","doi-asserted-by":"crossref","first-page":"vi23","DOI":"10.1093\/rheumatology\/key152","article-title":"Therapies in ankylosing spondylitis-from clinical trials to clinical practice","volume":"57","author":"Tahir","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.clinsp.2026.101147_bib0008","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.clinsp.2026.101147_bib0009","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J Immunol"},{"issue":"10","key":"10.1016\/j.clinsp.2026.101147_bib0010","first-page":"17362","article-title":"Elevated serum levels of IL-6 and IL-17 may associate with the development of ankylosing spondylitis","volume":"8","author":"Liu","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.clinsp.2026.101147_bib0011","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/785705","article-title":"Serum IL-6 and IL-23 levels and their correlation with angiogenic cytokines and disease activity in ankylosing spondylitis, psoriatic arthritis, and SAPHO Syndrome","volume":"2015","author":"Przepiera-B\u0119dzak","year":"2015","journal-title":"Mediators Inflamm"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101147_bib0012","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3892\/mmr.2017.6248","article-title":"Role of HLA-B27 in the pathogenesis of ankylosing spondylitis (Review)","volume":"15","author":"Chen","year":"2017","journal-title":"Mol Med Rep"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101147_bib0013","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.micinf.2009.04.003","article-title":"IL-17 and Th17 cells in human inflammatory diseases","volume":"11","author":"Miossec","year":"2009","journal-title":"Microbes Infect"},{"key":"10.1016\/j.clinsp.2026.101147_bib0014","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/5617431","article-title":"Changes in serum cytokines may predict therapeutic efficacy of tofacitinib in rheumatoid arthritis","volume":"2019","author":"Li","year":"2019","journal-title":"Mediators Inflamm"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101147_bib0015","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.clinsp.2026.101147_bib0016","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.clinsp.2026.101147_bib0017","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.clinsp.2026.101147_bib0018","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","volume":"80","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinsp.2026.101147_bib0019","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.clinsp.2026.101147_bib0020","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"Bmj"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101147_bib0021","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101147_bib0022","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/09733698241281409","article-title":"Efficacy and safety of tofacitinib in ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"20","author":"Harish","year":"2025","journal-title":"Indian Journal of Rheumatology"},{"issue":"8","key":"10.1016\/j.clinsp.2026.101147_bib0023","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3899\/jrheum.2023-1198","article-title":"Efficacy and safety of tofacitinib in ankylosing spondylitis by baseline C-reactive protein level: post hoc analysis of phase II and phase III clinical trials","volume":"51","author":"Deodhar","year":"2024","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101147_bib0024","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40744-024-00726-6","article-title":"Tofacitinib efficacy\/safety in patients with ankylosing spondylitis by baseline body mass index: a post hoc analysis of phase 2\/3 trials","volume":"12","author":"Norton","year":"2025","journal-title":"Rheumatol Ther"},{"issue":"6","key":"10.1016\/j.clinsp.2026.101147_bib0025","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinsp.2026.101147_bib0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejim.2022.04.007","article-title":"Efficacy and safety of Janus kinase inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis","volume":"102","author":"Li","year":"2022","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.clinsp.2026.101147_bib0027","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1093\/rheumatology\/keab740","article-title":"A review of JAK-STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition","volume":"61","author":"McInnes","year":"2022","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.clinsp.2026.101147_bib0028","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00393-020-00948-3","article-title":"Janus kinase inhibitors for treating active ankylosing spondylitis: a meta-analysis of randomized controlled trials","volume":"81","author":"Lee","year":"2022","journal-title":"Z Rheumatol"},{"issue":"9","key":"10.1016\/j.clinsp.2026.101147_bib0029","article-title":"Assessment of the safety of tofacitinib among patients with psoriasis: a systematic review and meta-analysis","volume":"16","author":"Alqahtani","year":"2024","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.clinsp.2026.101147_bib0030","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1807593226002747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T11:32:41Z","timestamp":1793964761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1807593226002747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"alternative-id":["S1807593226002747"],"URL":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101147","relation":{},"ISSN":["1807-5932"],"issn-type":[{"value":"1807-5932","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of tofacitinib in ankylosing spondylitis patients: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinsp.2026.101147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 HCFMUSP. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}],"article-number":"101147"}}